Carboplatin is currently being used as an anticancer drug against human cancers. However, high dose of carboplatin chemotherapy resulted in ototoxicity in cancer patients. Carboplatin-induced ototoxicity was related to oxidative stress to the cochlea and inner hair cell loss in animals. It is likely that initial oxidative injury spreads throughout the neuroaxis of the auditory system later. The study aim was to evaluate carboplatin-induced hearing loss and oxidative injury to the central auditory system (inferior colliculus) of the rat. Male Wistar rats were divided into two groups of seven animals each and treated as follows: (1) control (normal saline, intraperitoneal [IP]) and (2) carboplatin (256 mg/kg, IP). Auditory brain-evoked responses (ABRs) were recorded before and 4 days after treatments. The animals were sacrificed on the 4th day and inferior colliculus from brain stem and cerebellum were isolated and analyzed. Carboplatin significantly elevated the hearing threshold shifts at clicks, 2-, 4-, 8-, 16-, and 32-k Hz tone burst stimuli. Carboplatin significantly increased nitric oxide and lipid peroxidation, xanthine oxidase, and manganese superoxide dismutase activities in the inferior colliculus, but not in the cerebellum, indicating an enhanced flux of free radicals in the central auditory system. Carboplatin significantly depressed the reduced to oxidized glutathione ratio, antioxidant enzyme activities, such as copper-zinc superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, and glutathione S-transferase, and enzyme protein expressions in the inferior colliculus, but not in the cerebellum, 4 days after treatment. The data suggest that carboplatin induced oxidative injury specifically in the inferior colliculus of the rat leading to hearing loss.
Aebi, N.1984. Catalase in vitro. Methods Enzymol.105:121–126.
2.
Alberts, D. S.1995. Carboplatin versus cisplatin in ovarian cancer. Semin. Oncol.22:88–90.
3.
Anderson, M. E., A. Naganuma, and A. Meister. 1990. Protection against cisplatin toxicity by administration of glutathione ester. FASEB J.4:3251–3255.
4.
Bauer, F. P., M. Westhofen, and W. Kehrl. 1992. The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors. Laryngorhinootologie71:412–415.
5.
Bohm, S., S. Oriana, G. Spatti, F. Di Re, G. Breasciani, C. Pirovano, I. Grosso, C. Martini, A. Caraceni, S. Pilotti, and F. Zunini. 1999. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology57:115–120.
6.
Bolis, G., G. Scarfone, S. Tateo, G. Mangili, A. Villa, and F. Parazzini. 2001. Response and toxicity to topotecan in sensitive in sensitive ovarian cancer cases with small residual disease after first line treatment with carboplatinum and paclitaxel. Gynecol. Oncol.80:13–15.
7.
Carlberg, I., and B. Mannervik. 1985. Glutathione reductase. Methods Enzymol.113:484–490.
8.
Cavaletti, G., G. Bogliun, A. Zincone, L. Marzorati, P. Melzi, L. Frattola, M. Marzola, C. Bonazzi, M. G. Cantu, S. Chiari, A. Galli, M. Bregni, and M. Gianni. 1998. Neuro and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res.18:3797–3802.
9.
Chamberlain, M. C.2002. Treatment of intracranial metastatic esthesion neuroblastoma. Cancer95:243–248.
10.
Church, M. W., J. A. Kaltenbach, B. W. Blakley, and D. L. Bungio. 1995. The comparative effects of sodium thiosulfate diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear. Res.86:195–203.
11.
Conlon, B. J., J. M. Aran, J. P. Erre, and D. W. Smith. 1999Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant alpha-lipoic acid. Hear. Res.128:40–44.
12.
De Lauretis, A., B. De Capua, M. T. Barbieri, L. Bellussi, and D. Passali. 1999. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand. Audiol.28:139–143.
13.
Ding, L., S. L. Mc Fadden, and R. J. Salvi. 2002. Calpain immunoreactivity and morphological damage in chinchilla inner ear after carboplatin. J. Assoc. Res. Otolaryngol.3:68–79.
14.
Ehert, G.1997. The auditory mid brain, a shunting yard of acoustical information processing. In The central auditory system, eds. G. Ehert and R. Romand, 259–316. New York: Oxford University Press.
15.
Ettinger, D. S.1998. The role of carboplatin in the treatment of small-cell lung cancer. Oncology12:36–43.
16.
Evans, P., and B. Halliwell. 1999. Free radicals and hearing, cause, consequence and criteria. Ann. N.Y. Acad. Sci.884:19–40.
17.
Farms, W. B., D. A. Godfray, and A. Askari. 1993. Effect of copper deficient diet on metabolism in rat auditory structures. Hear. Res.67:45–50.
18.
Fariss, M. W., and D. J. Reed. 1987. High performance liquid chromatography of thiols and disulfides: Dinitrophenol derivatives. Methods Enzymol.143:101–109.
19.
Flohe, L., and W. Gunzler. 1984. Assays of glutathione peroxidase. Methods Enzymol.105:114–121.
Habig, W. H., M. J. Pabst, and W. B. Jakoby. 1974. Glutathione-S-transferases. The first step in mercapturic acid formation. J. Biol. Chem.249:7130–7139.
22.
Hamers, F. P. T., J. H. Brakkee, E. Cavalletti, M. Tedeschi, L. Marmonti, G. Pezzoni, J. P. Neijt, and W. H. Gispen. 1993. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res.53:544–549.
23.
Hofstetter, P., D. Ding, and R. Salvi. 2000. Induction of spontaneous otoacoustic emission in chinchillas from carboplatin-induced inner hair cell loss. Hear. Res.150:132–136.
24.
Homi, H. M., J. J. Freitas, R. Curi, I. T. Velasco, and B. A. Junior. 2002. Changes in superoxide dismutase and catalase activities of rat brain regions during early global transient ischemia/reperfusion. Neurosci. Lett.333:37–40.
25.
Hu, B. H., S. L. Mc Fadden, R. J. Salvi, and D. Henderson. 1999. Intracochlear infusion of buthionine sulfoximine potentiates carboplatin ototoxicity in the chinchilla. Hear. Res.128:125–134.
26.
Husain, K., C. Morris, C. Whitworth, G. L. Trammell, L. P. Rybak, and S. M. Somani. 1998. Protection by ebselen against cisplatin induced nephrotoxicity: Antioxidant system. Mol. Cell Biochem.178:127–133.
27.
Husain, K., R. B. Scott, C. Whitworth, S. M. Somani, and L. P. Rybak. 2001a. Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear. Res.151:71–78.
28.
Husain, K., and S. M. Somani. 1998. Effect of exercise training and chronic ethanolingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat. Prog. Neuro-Psychopharmacol. Biol. Psychiat.22:411–423.
29.
Husain, K., C. Whitworth, S. M. Somani, and L. P. Rybak. 2001b. Carboplatin-induced oxidative stress in rat cochlea. Hear. Res.158:14–22.
30.
Ikeda, K., H. Sunose, and T. Takasaka. 1993. Effects of free radicals on the intracellular calcium concentration in the isolated outer hair cell of the guinea pig cochlea. Acta Otolaryngol.13:137–141.
31.
Kennedy, I. C., B. M. Fitzharris, B. M. Colls, and C. H. Atkinson. 1990. Carboplatin is ototoxic. Cancer Chemother. Pharmacol.26:232–234.
32.
Lautermann, J., S. A. Crann, J. Mc Laren, and J. Schacht. 1997. Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hear Res.114:75–82.
33.
Los, G., M. J. H. Van Vugt, L. D. Engelse, and H. M. Pinedo. 1993. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem. Pharmacol.46:1229–1237.
34.
Mc Keage, M. J.1995. Comparative adverse effect profiles of platinum drugs. Drug Safety13:228–244.
35.
Meyer, W. H., C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, M. Neel, and B. D. Fletcher. 2001. Carboplatin/ifosfomide window therapy for osteosarcoma: Results of the St. Jude Children's Hospital OS-91 Trial. J. Clin. Oncol.19:171–182.
36.
Mie, Y., K. R. Gawai, Z. Nie, V. Ramkumar, and R. H. Helfert. 1999. Age-related reductions in the activities of antioxidant enzymes in the rat inferior colliculus. Hear. Res.135:169–180.
37.
Misra, H. P., and I. Fridovich. 1972. The role of superoxide anion in the autooxidation of the epinephrine and a sample assay for superoxide dismutase. J. Biol. Chem.247:3170–3175.
38.
Mount, R. J., S. Takeno, M. Wake, and R. V. Harrison. 1995. Carboplatin ototoxicity in the chinchilla: Lesions of the vestibular sensory epithelium. Acta Otolaryngol.519:60–65.
39.
Muldoon, L. L., M. A. Pagel, R. A. Kroll, R. E. Brummett, N. D. Doolittle, E. G. Zuhowski, M. J. Egorin, and E. A. Neuwelt. 2000. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res.6:309–315.
40.
Muller, D. P. R.1997. Neurological disease. In Antioxidants in disease mechanisms and therapy, ed. H. Sies, 557–580. New York: Academic Press.
41.
Neuwelt, E. A., R. E. Brummet, N. D. Doolittle, L. L. Muldoon, R. A. Kroll, M. A. Pagel, R. Dojan, V. Church, L. G. Remsen, and J. S. Bubalo. 1998. First evidence of otoprotection against caboplatin-induced hearing loss with a two compartment system in patient with central nervous system malignancy using sodium thiosulfate. J. Pharmacol. Exp. Ther.286:77–84.
42.
Obermair, A., P. Speiser, M. Thoma, A. Kaider, H. Salzer, C. Dittrich, and R. Sevelda. 1998. Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin. Int. J. Oncol.13:1023–1030.
43.
Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animals and tissue by thiobarbituric acid reaction. Anal. Biochem.95:351–358.
44.
Pal, R., R. Nath, and D. Gill. 1993. Lipid peroxidation and antioxidant defense enzymes in various regions of adult rat brain after coexposure to cadmium and ethanol. Pharmacol. Toxicol.73:209–214.
45.
Ravi, R., S. M. Somani, and L. P. Rybak. 1995. Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacol. Toxicol.76:386–394.
46.
Read, S. M., and D. H. Northcole. 1981. Minimization of variation in the response to different protein of the coomassie blue G dye-binding assay for protein. Anal. Biochem.116:53–64.
47.
Rybak, L. P., R. Ravi, and S. M. Somani, 1995. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fundam. Appl. Toxicol.26:293–300.
48.
Schweitzer, V. G.1993. Ototoxicity of chemotherapeutic agents. Otolaryngol. Clin. North Am.26:805–832.
49.
Siddik, Z. H., D. R. Newell, F. E. Boxall, and K. R. Harrap. 1987. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem. Pharmacol.36:1925–1932.
50.
Singh, N. M., L. Bogavac, V. Kalimanovska, Z. Jelic, and S. Spasic. 1987. Spectrophotometric assay of xanthine oxidase with 2,2-azino-di-(3-methylbenzthiazoline-6-sulphonate) (ABST) as chromogen. Clin. Chem. Acta162:29–36.
51.
Sokoloff, L., M. Reivich, C. Kennedy, M. H. Des Rosirs, C. S. Patlalak, K. D. Pettigrew, O. Sakurada, and M. Shinohara. 1977. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization, theory, procedure and the normal values in the conscious and anesthetized albino rats. J. Neurochem.28:897–916.
52.
Song, B. B., and J. Schacht. 1996. Variable efficiency of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hear. Res.94:87–93.
53.
Steiner, H., L. Holtl, W. Wirtenberger, A. P. Berger, G. Bartsch, and A. Hobisch. 2002. Long term experience with carboplatin monotherapy for clinical stage I seminoma: A retrospective single center study. Urology60:324–328.
54.
Taudy, M, J. Syka, J. Popelar, and L. Ulehlova. 1992. Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology31:293–299.
55.
Teranishi, M., T. Nakashima, and T. Wakabayashi. 2001. Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear. Res.151:61–70.
56.
Wake, M., S. Takeno, R. J. Mount, and R. V. Harrison. 1996. Recording from the inferior colliculus following cochlear inner hair cell damage. Acta Otolaryngol116:714–720.
57.
Wandt, H., J. Birkmann, T. Denzel, K. Schafer, G. Schwab, D. Pilz, H. Egger, A. Both, and W. M. Gallmeir. 1999. Sequential cycles of high dose chemotherapy with dose escalation carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: A phase I/II study in advanced ovarian cancer. Bone Marrow Transplant23:763–770.
58.
Watanabe, K., A. Hess, W. Bloch, and O. Michel. 2000. Nitric oxide synthase inhibitor suppresses the ototoxic side effects of cisplatin in guinea pigs. Anticancer Drugs11:401–406.
59.
Watanabe, K., K. Jinnouchi, A. Hess, O. Michel, S. Baba, and T. Yagi. 2002. Carboplatin induces less apoptosis in the cochlea of guinea pig than cisplatin. Chemotherapy48:82–87.
60.
Younes, M., and C. P. Siegers. 1981. Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo. Chem. Biol. Interact.34:257–266.
